NCT04475835 is a NA clinical trial of Bivalirudin in STEMI With Multivessel Coronary Disease, sponsored by First Affiliated Hospital Xi'an Jiaotong University.

Who is sponsoring NCT04475835?

NCT04475835 is sponsored by First Affiliated Hospital Xi'an Jiaotong University.

What drugs are being tested in NCT04475835?

Interventions in NCT04475835: Bivalirudin, Heparin.

What condition does NCT04475835 study?

NCT04475835 studies STEMI With Multivessel Coronary Disease.

Is NCT04475835 still recruiting?

NCT04475835 is currently status unknown. Last updated 26 April 2022.

Last reviewed 2022-04-26 · How we verify

NCT04475835

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study on Safety and Efficacy of Bivalirudin During Short-term Intervention of Non-infarction Related Artery for Acute ST-segment Elevation Myocardial Infarction After Emergency Percutaneous Coronary Intervention

Status unknown NA Last updated 26 April 2022

What this trial tests

NA trial testing Bivalirudin in STEMI With Multivessel Coronary Disease in 100 participants. Status unknown.

Timeline

12 January 2021

Primary endpoint
1 December 2022

1 December 2022

Quick facts

Lead sponsor	First Affiliated Hospital Xi'an Jiaotong University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	12 January 2021
Primary completion	1 December 2022
Estimated completion	1 December 2022
Sites	1 location across China

Drugs / interventions tested

Bivalirudin (BIVALIRUDIN) — full drug profile →
Heparin (HEPARIN) — full drug profile →

Conditions studied

STEMI With Multivessel Coronary Disease — all drugs for STEMI With Multivessel Coronary Disease →

Sponsor

First Affiliated Hospital Xi'an Jiaotong University

Who can join

18 and older, any sex, with STEMI With Multivessel Coronary Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Net adverse clinical events (NACE)
Time frame: 30 days
A composite of major adverse cardiac or cerebral events (all-cause death, reinfarction, ischemia-driven target vessel revascularization, or stroke) or any bleeding as defined by BARC definition (grades 1-5). BARC=Bleeding Academic Research Consortium

Sponsor's own description

This is a randomized, open label, cohort study, in which a total of 100 patients will be enrolled and randomly assigned to receive bivalirudin or heparin in a 1:1 ratio during short-term intervention of non-infarction related artery for acute ST-segment elevation myocardial infarction after emergency percutaneous coronary intervention. NACE, MACE, any type of BARC bleeding, stent thrombosis will be evaluated in 30 days and 6 months after recruitment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Bivalirudin

Trials testing the same drug.

NCT05959252 — BivaLirudin versUS Heparin in Extracorporeal Membrane Oxygenation · Phase 2 · recruiting
NCT05984537 — A Study on the Impact of Bivalirudin Usage During PCI for High-risk Plaques on Post-PCI Coronary Microcirculation. · Phase 4 · recruiting
NCT05334654 — Bivalirudin Versus Enoxaparin in Critically Ill COVID-19 Patients · NA · completed
NCT04195997 — Multi-center Application of Bivalirudin in Left Atrial Appendage Occlusion · Phase 4 · unknown
NCT04185077 — Bivalirudin in Late PCI for Oatients With STEMI · Phase 4 · unknown

Other First Affiliated Hospital Xi'an Jiaotong University trials

Trials by the same sponsor.

NCT07389460 — Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND) · Phase 3 · not yet recruiting
NCT07170176 — Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine · NA · recruiting
NCT07168291 — Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma · EARLY_PHASE1 · not yet recruiting
NCT06775782 — Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke Due to Large Artery Atherosclerosis · NA · recruiting
NCT07266467 — Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Dis · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04475835 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital Xi'an Jiaotong University
Last refreshed: 26 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04475835.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing